ATE449603T1 - Verwendung von duloxetine zur behandlung von fibromyalgie - Google Patents

Verwendung von duloxetine zur behandlung von fibromyalgie

Info

Publication number
ATE449603T1
ATE449603T1 AT99969026T AT99969026T ATE449603T1 AT E449603 T1 ATE449603 T1 AT E449603T1 AT 99969026 T AT99969026 T AT 99969026T AT 99969026 T AT99969026 T AT 99969026T AT E449603 T1 ATE449603 T1 AT E449603T1
Authority
AT
Austria
Prior art keywords
duloxetine
treat fibromyalgia
treat
fibromyalgia
naphthalenyloxy
Prior art date
Application number
AT99969026T
Other languages
English (en)
Inventor
David Goldstein
Smriti Iyengar
Rosa Simmons
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of ATE449603T1 publication Critical patent/ATE449603T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT99969026T 1998-09-15 1999-09-10 Verwendung von duloxetine zur behandlung von fibromyalgie ATE449603T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10037798P 1998-09-15 1998-09-15
PCT/US1999/020986 WO2000015223A1 (en) 1998-09-15 1999-09-10 Treatment of persistent pain

Publications (1)

Publication Number Publication Date
ATE449603T1 true ATE449603T1 (de) 2009-12-15

Family

ID=22279434

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99969026T ATE449603T1 (de) 1998-09-15 1999-09-10 Verwendung von duloxetine zur behandlung von fibromyalgie

Country Status (15)

Country Link
US (1) US6596756B1 (de)
EP (1) EP1113797B1 (de)
JP (1) JP2002524513A (de)
CN (1) CN1149991C (de)
AT (1) ATE449603T1 (de)
AU (1) AU746887B2 (de)
BR (1) BR9913671A (de)
CA (1) CA2344057C (de)
CY (1) CY1110581T1 (de)
DE (1) DE69941712D1 (de)
DK (1) DK1113797T3 (de)
ES (1) ES2335067T3 (de)
PT (1) PT1113797E (de)
SI (1) SI1113797T1 (de)
WO (1) WO2000015223A1 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2451288A1 (en) * 2001-07-31 2003-02-13 Pharmacia & Upjohn Company Treatment of chronic pain with 3-heterocyclyl- and 3-cycloalkyl-3-aryloxypropanamines
US6602911B2 (en) * 2001-11-05 2003-08-05 Cypress Bioscience, Inc. Methods of treating fibromyalgia
CN1662231A (zh) * 2002-04-24 2005-08-31 柏树生物科学公司 包括应激相关障碍在内的功能性躯体障碍的预防与治疗
AU2003227519A1 (en) * 2002-05-30 2003-12-19 Head Explorer A/S The use of milnacipran for the treatment of tension-type headache
JP2006500427A (ja) * 2002-08-29 2006-01-05 アラクノーバ・セラピューティックス・リミテッド （４−（２−フルオロフェニル）−６−メチル−２−（１−ピペラジニル）チエノ［２，３−ｄ］ピリミジンの新規治療的使用
US20050272805A1 (en) * 2002-11-19 2005-12-08 Detke Michael J Treatment of gastrointestinal disorders with duloxetine
US20100256179A1 (en) * 2004-03-26 2010-10-07 Ucb Pharma Gmbh Combination therapy for pain in painful diabetic neuropathy
US20050233980A1 (en) * 2004-04-20 2005-10-20 Boehringer Ingelheim International Gmbh CGRP-antagonist in combination with a serotonin-reuptake inhibitor for the treatment of migraine
MX2007000793A (es) * 2004-07-24 2007-03-21 Esteve Labor Dr Uso de compuestos activos sobre el receptor sigma para el tratamiento de alodinia mecanica.
CN100362996C (zh) * 2004-10-14 2008-01-23 上海医药工业研究院 一种度洛西汀肠溶微丸胶囊及其制备方法
TWI306858B (en) * 2004-12-23 2009-03-01 Teva Pharma Process for preparing pharmaceutically acceptable salts of duloxetine and intermediates thereof
MX2007010931A (es) * 2005-03-08 2007-10-16 Teva Pharma Formas cristalinas de (s)-(+)-n,n-dimetil-3-(1-naftaleniloxi)-3-(2 -tienil)propanamina oxalato y la preparacion ellas.
US20070116643A1 (en) * 2005-07-01 2007-05-24 Concert Pharmaceuticals Inc. Novel aryloxypropanamines
EP1754476A1 (de) * 2005-08-18 2007-02-21 Schwarz Pharma Ag Lacosamid (SPM 927) zur Behandlung von Myalgien, z.B. Fibromyalgie
WO2007062119A1 (en) * 2005-11-23 2007-05-31 Auspex Pharmaceuticals, Inc. Substituted aryloxypropylamines with serotoninergic and/or norepinephrinergic activity
WO2007139984A2 (en) * 2006-05-23 2007-12-06 Teva Pharmaceutical Industries Ltd. Duloxetine hcl polymorphs
US8735356B2 (en) 2006-06-15 2014-05-27 Ucb Pharma Gmbh Anticonvulsant combination therapy
WO2008009665A1 (en) * 2006-07-19 2008-01-24 Boehringer Ingelheim International Gmbh Treatment of pain
TW200846003A (en) * 2007-03-15 2008-12-01 Astellas Pharma Inc Novel prophylactic and/or therapeutic agent for diabetic neuropathy
US8708961B2 (en) * 2008-01-28 2014-04-29 Medsolve Technologies, Inc. Apparatus for infusing liquid to a body
WO2010150219A1 (en) 2009-06-25 2010-12-29 Wockhardt Research Centre Pharmaceutical composition of duloxetine or pharmaceutically acceptable salts thereof
HUE042593T2 (hu) * 2010-03-09 2019-07-29 Alkermes Pharma Ireland Ltd Alkoholnak ellenálló enterális gyógyszerkészítmények
WO2016062285A1 (zh) * 2014-10-24 2016-04-28 朗齐生物医学股份有限公司 神经系统疾病用药在制备抗癌医药组合物中的应用
JP2020029447A (ja) * 2018-06-25 2020-02-27 大原薬品工業株式会社 腸溶性高分子及び抗付着剤を含有する顆粒
JP7390830B2 (ja) * 2019-09-11 2023-12-04 日本食品化工株式会社 医薬活性化合物の苦味抑制剤及び苦味抑制方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4956388A (en) * 1986-12-22 1990-09-11 Eli Lilly And Company 3-aryloxy-3-substituted propanamines
CA2134038C (en) * 1994-06-16 1997-06-03 David Taiwai Wong Potentiation of drug response
US5508276A (en) 1994-07-18 1996-04-16 Eli Lilly And Company Duloxetine enteric pellets
ZA958725B (en) 1994-10-20 1997-04-16 Lilly Co Eli Treatment of disorders with duloxetine
JP2000506863A (ja) 1996-03-11 2000-06-06 イーライ・リリー・アンド・カンパニー 間質性膀胱炎の治療または予防方法
CN1494907A (zh) * 1996-03-25 2004-05-12 治疗疼痛的药物组合物
US5912256A (en) * 1996-06-20 1999-06-15 Eli Lilly And Company Compounds having effects on serotonin-related systems

Also Published As

Publication number Publication date
DE69941712D1 (de) 2010-01-07
US6596756B1 (en) 2003-07-22
AU746887B2 (en) 2002-05-02
CA2344057A1 (en) 2000-03-23
EP1113797A4 (de) 2006-07-05
CY1110581T1 (el) 2015-04-29
WO2000015223A1 (en) 2000-03-23
DK1113797T3 (da) 2010-02-01
JP2002524513A (ja) 2002-08-06
ES2335067T3 (es) 2010-03-18
SI1113797T1 (sl) 2010-02-26
EP1113797B1 (de) 2009-11-25
EP1113797A1 (de) 2001-07-11
AU1197200A (en) 2000-04-03
BR9913671A (pt) 2001-06-05
CN1149991C (zh) 2004-05-19
CA2344057C (en) 2008-11-18
CN1316904A (zh) 2001-10-10
PT1113797E (pt) 2009-12-21

Similar Documents

Publication Publication Date Title
DE69941712D1 (de) Verwendung von duloxetine zur behandlung von fibromyalgie
RU94035996A (ru) Способ получения /s/-/+/-n,n-диметил-3-/1-нафталинилокси/-3-/2-тиенил/пропанамина и его фосфорнокислой соли и фосфорнокислая соль
TR200000755T2 (tr) Karşıt olma-karşı gelme bozukluğunun tedavisi.
EA200000351A1 (ru) Лечение кондуктивных нарушений
ATE365042T1 (de) Verwendung von morpholinol zur behandlung von sexuellen funktionsstörungen
EA199700208A1 (ru) Тиенил-, фурил-, пирролил- и дифенилсульфонамиды и их производные, модулирующие активность эндотелина
ATE279181T1 (de) Verwendung von 5ht-6 antagonisten zur behandlung adhd
ATE258919T1 (de) Verwendung von alkylierten iminozuckern zur behandlung von multipler medikamentenresistenz
UA42716C2 (uk) ГЕМІСОЛЬВАТИ 6-ГІДРОКСИ-2-(4-ГІДРОКСИФЕНІЛ)-3-[4-(ПІПЕРИДИНОЕТОКСИ)БЕНЗОЇЛ]БЕНЗО[b]ТІОФЕНГІДРОХЛОРИДУ
DE60142712D1 (de) Verwendung von Botulinum Toxin zur Behandlung von Eingweideschmerzen
UA43385C2 (uk) Спосіб лікування синдрому дефіциту уваги/гіперактивності
ATE207356T1 (de) Verwendung von tiagabin zur behandlung von schlafstörungen
ATE308364T1 (de) Verwendung von cyanochinolinen zur behandlung oder inhibierung von dickdarmpolypen
DE69615445D1 (de) Kompilierer zur Verbesserung der Leistung von Datencachespeichern
ATE298566T1 (de) Proteintyrosine-kinaseinhibitoren zur behandlung der osteoarthritis
JP2002524513A5 (de)
ATE279921T1 (de) Verwendung von antikonvulsiven derivaten zur behandlung der cluster headache
BR9507956A (pt) 2-amino-3-aroil-benzo [beta] tiofenos e processos para preparare usar os mesmos para produzi 6-hidróxi-2-(4-hidroxifinil)-3-[4-(2-aminoetóxi)-benzoil]benzo [beta] tiofenos
DE60014928D1 (de) Retinoide zur behandlung von emphysem
DE69920205D1 (de) Verwendung von metall-proteinase-inhibitoren, um das wachstum der haare oder körperhaare zu induzieren und/oder zu stimulieren und/oder den haarausfall zu verlangsamen
DE59202663D1 (de) Verwendung eines UV-Strahlers zur Behandlung von Oberflächen.
ATE410181T1 (de) Verwendung von intereferon gamma zur behandlung von herzhypertrophie
DE69606466D1 (de) Verwendung eines Pulvers oder eines Extraktes von Guava zur Behandlung von Allergien
ATE326969T1 (de) Verwendung von apomorphin zur behandlung der vorzeitigen ejakulation
EA200200948A1 (ru) Лечение псориаза

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1113797

Country of ref document: EP